Molecular Mechanisms of Endothelial Dysfunction in Type 2 Diabetes Mellitus.

Trial Profile

Molecular Mechanisms of Endothelial Dysfunction in Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Meglitinide; Pioglitazone; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 30 May 2012 Actual initiation date (Mar 2007), trial company, lead trial centres and investigator a added as reported by ClinicalTrials.gov.
    • 30 May 2012 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 30 May 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT00816218).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top